Stock Analysis
Cytokinetics Inc.CYTK
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy28 analystsPrice is 22% of the way from the year's low to its high.
Cash covers 82% of debt · Q2 2026.
PMP Verdict
Weak fundamentals
Risks
- Profitability0
- Quality11
Weak fundamentals — valuation is the only support.
Market context
-3.1% today· Z 0.8σ
What's happening with CYTK
Profile
profitability, moat, earnings quality, growth, valuation and financial health lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-6.7%)0/25
- P/S (128.9x)0/25
- EV/EBIT (n/a)10/25
- Growth12/100 · Weak
- Revenue CAGR (5.7%)12/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-655.8%)0/25
- ROE (n/a)0/25
- Net margin (-1321.3%)0/25
- Operating margin (-1046.1%)0/25
- Financial Health40/100 · Weak
- Altman Z (-0.50)3/25
- Current ratio (6.66)25/25
- Interest coverage (-13.4x)0/25
- Net cash / debt (D/A 13%)12/25
- Quality11/100 · Weak
- Piotroski F (2/9)5/25
- Beneish M (-0.83)6/25
- FCF conversion (n/a)0/25
- Margin stability (σ 5743.5%)0/25
- Moat0/100 · Weak
- ROIC >12% years (n/a)0/25
- Median gross margin (n/a)0/25
- FCF-positive years (1/10 yrs)0/25
- Worst-year net margin (worst -6988.6%)0/25
Risk Flags
- ⚠Altman Z -0.5 — distress-zone balance sheet
- ⚠Beneish M -0.83 — earnings-manipulation flag
- ⚠Negative FCF margin (-2.0%) — burning cash
- ⚠SBC 188.1% of revenue — real dilution cost
- ⚠9 loss-making years in recent history
About Cytokinetics Inc.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Show more
The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Headquarters: SOUTH SAN FRANCISCO, CA · Employees: 673 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF155.5xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-6.7%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -17.2%–-1.0% · 49th pct
P/S (TTM)128.86xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 20.2x–2095.8x · 46th pct
EV/EBITDA1169.5xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales145.0xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B RatioNeg. EquityC
Grade C: BuybacksPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-0.22A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-655.8%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROENeg. EquityC
Grade C: BuybacksReturn on Equity. Neg. equity = heavy buybacks
ROA-59.0%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-1321.3%D
Grade D: LowNet Income / Revenue
Operating Margin-1046.1%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin—
Gross Profit / Revenue
FCF Margin-200.0%D
Grade D: LowFCF / Revenue
True FCF Margin-1046.2%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
12ERevenue CAGR5.7%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue188.1%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
40D+Altman Z-Score-0.50D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio6.66xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio6.56xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-13.4xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity—
Debt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.82xC
Grade C: PartialCash covers how much of total debt. >1 = could repay all debt from cash
Quality
11EPiotroski F-Score2/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score-0.83D
Grade D: RiskyEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability5743.5%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue37.3%D
Grade D: HeavyTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.04xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Blum Robert I Filed | Blum Robert I | Option exercise | -7500 | |
Blum Robert I Filed | Blum Robert I | SellOpen market sale | -7500 | |
Blum Robert I Filed | Blum Robert I | Option exercise | +7.5K | |
Malik Fady Ibraham Filed | Malik Fady Ibraham | Option exercise | -3500 | |
Malik Fady Ibraham Filed | Malik Fady Ibraham | SellOpen market sale | -3500 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Malik Fady Ibraham Filed | Malik Fady Ibraham | Option exercise | +3.5K | |
Blum Robert I Filed | Blum Robert I | Option exercise | -7500 | |
Blum Robert I Filed | Blum Robert I | SellOpen market sale | -7500 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years—
Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)—
Median annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years1/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-6988.6%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$8.40
Cash & short-term investments per share (Finnhub)
Book Value / Share$0.92
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$1.42B
Total debt obligations (short + long term)
Cash & Equiv.$1.17B
Cash and short-term investments
Net Debt$258.77M
Total Debt minus Cash. Negative = Net Cash position
Total Equity$-173.49M
Shareholders' equity (book value)
Asset / Liability0.92xD
Grade D: RiskyTotal Assets / Total Liabilities
Market
Market Cap$8.72B
Current Market Capitalization
Beta0.42B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Cytokinetics Inc. (CYTK)
CYTK is down 3.08% at the last close. Cytokinetics Inc. meets only 2 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of -0.50 is below the 1.81 distress threshold — an elevated financial-risk flag. Beneish M-Score of -0.83 is above the −1.78 flag threshold, a signal that reported earnings warrant closer scrutiny. Free-cash-flow margin is negative (-200%) — the business currently burns cash.
- Company has negative FCF, making debt repayment from operations difficult.
- Interest coverage of -13.4× leaves little room for earnings shocks.
- Cytokinetics Inc. posted a net loss in 9 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 20/100, CYTK trades at a premium to its historical multiples.
See how CYTK ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all CYTK moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 14 | Regular | 63.37 | +2.83% | 2.16 |
| Oct 14 | After-hours | 63.43 | +2.94% | 2.23 |
| Oct 5 | Regular | 62.77 | -4.31% | -2.28 |
| Oct 5 | After-hours | 62.70 | -4.42% | -2.35 |
Frequently Asked Questions about CYTK
What is the current Cytokinetics Inc. (CYTK) stock price?
CYTK is trading at $61.95 at the last market close, down 3.08% on the session. PreMarketPrice tracks CYTK pre-market, intraday and after-hours prices.
Is CYTK stock a buy right now?
PreMarketPrice's quantitative model rates Cytokinetics Inc.'s financial health at 40/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is CYTK stock overvalued?
Cytokinetics Inc. trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Cytokinetics Inc. report earnings?
No confirmed earnings date is currently scheduled for CYTK. The Earnings section lists recent reports and updates as dates are announced.
What sector does Cytokinetics Inc. operate in?
Cytokinetics Inc. operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Cytokinetics Inc. do?
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
About Cytokinetics Inc. (CYTK) Stock
Cytokinetics Inc. (CYTK) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Cytokinetics Inc. is trading at $61.95, down 3.08% on the day with a market capitalization of $8.7 billion. The financial health score for CYTK is 40/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for CYTK stock.
CYTK Stock Analysis & Key Metrics
On PreMarketPrice, you can track Cytokinetics Inc. (CYTK) across multiple dimensions:
- Pre-market price & movement: Real-time CYTK stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for CYTK with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Cytokinetics Inc. across multiple reporting periods.
- Financial health score: A composite score of 40/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for CYTK.
- Sector peers: Compare CYTK against 6 other healthcare stocks on key financial metrics.
Is CYTK a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Cytokinetics Inc. (CYTK) as an investment. The financial health score of 40/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Cytokinetics Inc. (CYTK) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.